ArticleAntimicrobial agents and chemotherapy2011
PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 73 citations in OpenAlex.
- Targeted Drug Delivery Strategies in Overcoming Antimicrobial Resistance: Advances and Future Directions.Pharmaceutics · 2025Review
- Folic Acid-Decorated Lipidic Nanocapsules Co-Loaded with Atorvastatin and Curcumin to Enhance Glioma Targeting in Mice.Pharmaceuticals (Basel, Switzerland) · 2025Article
- A Review Vancomycin Role in Gram Positive Biofilm-Associated Infections: Challenges and Emerging Solutions.Therapeutics and clinical risk management · 2025Review
- Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment.Signal transduction and targeted therapy · 2024Review
- Pharmacokinetic and Biomarker Quantification Studies on Vancomycin-Loaded PEGylated Liposomes and Its Potential to Reduce Vancomycin-Induced Kidney Injury: A Rat Study.Pharmaceutics · 2023Article
- Recent Advances in Antimicrobial Nano-Drug Delivery Systems.Nanomaterials (Basel, Switzerland) · 2022Review
- Antimicrobial Activity Enhancers: Towards Smart Delivery of Antimicrobial Agents.Antibiotics (Basel, Switzerland) · 2022Review
- Medicinal Chemistry of Inhibitors Targeting Resistant Bacteria.Current topics in medicinal chemistry · 2022Article
- Nanobiosystems for Antimicrobial Drug-Resistant Infections.Nanomaterials (Basel, Switzerland) · 2021Review
- Liposomes as Antibiotic Delivery Systems: A Promising Nanotechnological Strategy against Antimicrobial Resistance.Molecules (Basel, Switzerland) · 2021Review
- Development of nanoparticle-delivery systems for antiviral agents: A review.Journal of controlled release : official journal of the Controlled Release Society · 2021Review
- Nanotools for Sepsis Diagnosis and Treatment.Advanced healthcare materials · 2021Review
- Hybrid Pectin-Liposome Formulation against Multi-Resistant Bacterial Strains.Pharmaceutics · 2020Article
- Vancomycin-Induced Kidney Injury: Animal Models of Toxicodynamics, Mechanisms of Injury, Human Translation, and Potential Strategies for Prevention.Pharmacotherapy · 2020Review
- Encapsulation of collagen mimetic peptide-tethered vancomycin liposomes in collagen-based scaffolds for infection control in wounds.Acta biomaterialia · 2020Article
- Recent advances in the treatment of pathogenic infections using antibiotics and nano-drug delivery vehicles.Drug design, development and therapy · 2019Review
- Nanodelivery strategies for the treatment of multidrug-resistant bacterial infections.Journal of interdisciplinary nanomedicine · 2018Review
- Emerging Nanomedicine Therapies to Counter the Rise of Methicillin-Resistant Staphylococcus aureus.Materials (Basel, Switzerland) · 2018Review
- Prevention of Staphylococcus aureus Ventilator-Associated Pneumonia: Conventional Antibiotics Won't Cut It.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA) often cannot be cured by vancomycin treatment. Poor lung tissue and intracellular penetration limits the ability to achieve effective bactericidal levels, particularly in alveolar macrophages, where MRSA can evade phagocytic killing. Compared to standard formulations, liposome encapsulation has been shown to enhance vancomycin intracellular killing of MRSA. In this murine pharmacokinetic and biodistribution study, PEGylated liposomal vancomycin, compared to standard and non-PEGylated formulations, significantly prolonged blood circulation time and increased deposition in lung, liver, and spleen and yet reduced accumulation in kidney tissue. As a result of optimizing antimicrobial targeting of infected lung tissue and limiting renal parenchymal exposure, administration of PEGylated liposomal vancomycin may improve the efficacy of treatment of MRSA pneumonia and reduce the risk of nephrotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.